|
The Market For Follow-On Biologics: How Will It Evolve?
Henry Grabowski,
Iain Cockburn and
Genia Long
With spending on biologics rising and patent expiry approaching for several blockbuster biologics, Congress and the Food and Drug Administration are considering creating a clear pathway for so-called follow-on biologics. Differences between drugs and biologics will affect market outcomes in various ways. Conservative budget impacts are appropriate in the short run because fewer competitors will enter, and average prices will drop less than was the case following the Hatch-Waxman Act. Over the long term, intellectual property provisions will be important considerations for policymakers designing a pathway for follow-on biologics that balances price competition and innovation incentives.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
C. J Kelly and F. A Mir
Economics of biological therapies
BMJ,
August 21, 2009;
339(aug21_1):
b3276 - b3276.
[Full Text]
|
|
|
|
|
|
|
H. G. Grabowski and J. L. Moe
Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention
Cancer Prevention Research,
July 1, 2008;
1(2):
84 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Dudzinski and A. S. Kesselheim
Scientific and Legal Viability of Follow-on Protein Drugs
N. Engl. J. Med.,
February 21, 2008;
358(8):
843 - 849.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz
Projecting future drug expenditures--2007
Am. J. Health Syst. Pharm.,
February 1, 2007;
64(3):
298 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
